GSK To Buy US Biotech Biz IDRx For Up To $1.15B
British pharmaceutical giant GSK PLC said Monday that it will buy Boston-based IDRx Inc. for up to $1.15 billion as it seeks to expand its portfolio of treatments for gastrointestinal cancers....To view the full article, register now.
Already a subscriber? Click here to view full article